## Highlights of This Issue

### HIGHLIGHTS

#### AACR-FDA-NCI Cancer Biomarkers Collaborative Consensus Report: Advancing the Use of Biomarkers in Cancer Drug Development

Samir N. Khleif, James H. Doroshow, and William N. Hait; for the AACR-FDA-NCI Cancer Biomarkers Collaborative

#### ADAM-17: A Target to Increase Chemotherapeutic Efficacy in Colorectal Cancer?

Adam M. Lee and Robert B. Diasio

See article p. 3378

#### New Strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK

Giorgia Zadra, Carmen Priolo, Akash Patnaik, and Massimo Loda

#### Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response

Christine A. Pratilas and David B. Solit

#### The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment

Ivor Caro and Jennifer A. Low

#### BRCA1 Loss Preexisting in Small Subpopulations of Prostate Cancer Is Associated with Advanced Disease and Metastatic Spread to Lymph Nodes and Peripheral Blood

Natalia Bednarz, Elke Eltze, Axel Semjonow, Michael Rink, Antje Andreas, Lennart Mulder, Juliane Hannemann, Margit Fisch, Klaus Pantel, Heinz-Ulrich C. Weier, Krzysztof P. Bielawski, and Burkhard Brandt

### Cancer Therapy: Preclinical

#### Chemotherapy-Induced Activation of ADAM-17: A Novel Mechanism of Drug Resistance in Colorectal Cancer

Joan N. Kyula, Sandra Van Schaeybroeck, Joanne Doherty, Catherine S. Fenning, Daniel B. Longley, and Patrick G. Johnston

See commentary p. 3319

#### The Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Potently Induce Apoptosis in Chronic Lymphocytic Leukemia Cells In vitro and In vivo


#### Induction of Anti-Glioma Natural Killer Cell Response following Multiple Low-Dose Intracerebral CpG Therapy

Darya Alizadeh, Leying Zhang, Christine E. Brown, Omar Farrukh, Michael C. Jensen, and Behnam Badie

---

**Contents**

### Immunohistochemical Detection of EGF Mutation Using Mutation-Specific Antibodies in Lung Cancer

Atsuko Kitamura, Waki Hosoda, Eiichi Sasaki, Tetsuya Mitsudomi, and Yasushi Yatabe

### Gene Expression Profiling–Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome

Göran Jönsson, Christian Busch, Stian Knappskog, Jürgen Geisler, Hrvoje Miletić, Markus Ringnér, Johan R. Lillegaard, Åke Borg, and Per Eystein Lønning

### A Distinct Spectrum of Copy Number Aberrations in Pediatric High-Grade Gliomas

Dorine A. Bax, Alan Mackay, Suzanne E. Little, Diana Carvalho, Marta Viana-Pereira, Narinder Tamber, Anita E. Grigoriadis, Alan Ashworth, Rui M. Reis, David W. Ellison, Safa Al-Sarraj, Darren Hargrave, and Chris Jones

---

**The Journal of Clinical and Translational Research**

July 1, 2010 • Volume 16 • Number 13

---

**The Journal of Clinical and Translational Research**

www.aacrjournals.org
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>3409</td>
<td>Role of Type-1 IFNs in Antigloma Immunosurveillance—Using Mouse Studies to Guide Examination of Novel Prognostic Markers in Humans</td>
<td>Mitsugu Fujita, Michael E. Scheuerer, Stacy A. Decker, Heather A. McDonald, Gary Kohanbash, Edward R. Kastenhuber, Hisashi Kato, Melissa L. Bondy, John R. Ohlfest, and Hideho Okada</td>
</tr>
<tr>
<td>3420</td>
<td>Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects</td>
<td>Wei Zhang, Xiao-Dong Zhu, Hui-Chuan Sun, Yu-Quan Xiong, Peng-Yuan Zhuang, Hua-Xiang Xu, Ling-Qun Kong, Lu Wang, Wei-Zhong Wu, and Zhao-You Tang</td>
</tr>
<tr>
<td>3431</td>
<td>Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies</td>
<td>Nienke A. de Vries, Sophia W. Bruggeman, Danielle Huismans, Hilda I. de Vries, John Zevenhoven, Tessa Buckle, Bob C. Hamans, William P. Leenders, Jos H. Beijnen, Maarten van Lohuizen, Anton J.M. Berns, and Olaf van Tellingen</td>
</tr>
<tr>
<td>3452</td>
<td>Development of a Multiplexed Tumor-Associated Autoantibody-Based Blood Test for the Detection of Non–Small Cell Lung Cancer</td>
<td>Erin C. Farlow, Kalpa Patel, Sanjib Basu, Bao-Shiang Lee, Anthony W. Kim, John S. Coon, L. Penfield Faber, Philip Bonomi, Michael J. Liptay, and Jeffrey A. Borgia</td>
</tr>
<tr>
<td>3463</td>
<td>Molecular Analysis of Plasma DNA for the Early Detection of Lung Cancer by Quantitative Methylation-Specific PCR</td>
<td>Kimberly Laskie Ostrow, Mohammad O. Hoque, Myriam Loyo, Marianna Brait, Alissa Greenberg, Jill M. Siegfried, Jennifer R. Grandis, Autumn Gaither Davis, William L. Bigbee, William Rom, and David Sidransky</td>
</tr>
<tr>
<td>3473</td>
<td>Diverse Associations between ESRI Polymorphism and Breast Cancer Development and Progression</td>
<td>Shian-ling Ding, Jyh-Cherng Yu, Shou-Tung Chen, Gu-Cheng Hsu, Huan-Ming Hsu, Jar Yi Ho, Yu Hsin Lin, Chien-Ching Chang, Cathy S.I. Fann, Chun-Wen Cheng, Pei-Ei Wu, and Chen-Yang Shen</td>
</tr>
<tr>
<td>3485</td>
<td>Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells</td>
<td>Robert H. Vonderheide, Patricia M. LoRusso, Magi Khalil, Elaine M. Gartner, Divis Khaira, Denis Soulières, Prudence Dorazio, Jennifer A. Trosko, Jens Rüter, Gabriella L. Mariani, Tiziana Usari, and Susan M. Domchek</td>
</tr>
<tr>
<td>3507</td>
<td>Results from a Phase I Clinical Study of the Novel II-Key/HER-2/neu (776–790) Hybrid Peptide Vaccine in Patients with Prostate Cancer</td>
<td>Sonia A. Perez, Nikoletta L. Kallinteris, Stratos Biaías, Panagiotis K. Tzonis, Katerina Georgakopoulou, Marighoula Varla-Leftherioti, Michael Papamichail, Anastasios Thanos, Eric von Hoef, and Constantin N. Baxevanis</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: CLINICAL**

- Role of Type-1 IFNs in Antigloma Immunosurveillance—Using Mouse Studies to Guide Examination of Novel Prognostic Markers in Humans
- Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects
- Rapid and Robust Transgenic High-Grade Glioma Mouse Models for Therapy Intervention Studies
- Prognostic Significance of TRAIL Signaling Molecules in Stage II and III Colorectal Cancer
- Development of a Multiplexed Tumor-Associated Autoantibody-Based Blood Test for the Detection of Non–Small Cell Lung Cancer
ABOUT THE COVER

High-grade gliomas are among the deadliest of human cancers and appropriate glioma mouse models that are conveniently applicable for therapy-intervention studies can contribute to the finding of more efficacious treatments. Following the intracranial injection of lentiviral Cre-recombinase vectors into LoxP-conditional p53(or pten);Ink4a/Arf;K-Ras^V12;LucR mice, noninvasively visible high-grade gliomas arise with a short tumor latency that show features commonly found in human high-grade glioma, such as a high mitotic index, nuclear atypia, pseudopalisading necrosis, and giant cell formation. For further details, please see the article by de Vries and colleagues on page 3431 of this issue.